Also trades as: 1530.HK (HKSE) · $vol 61M

$2.15

+0.00 (+0.00%)

OTC · Healthcare · Biotechnology · Tech Score Sell · Power 48 · $5.4B mcap · 1.93B float · 0.0000% daily turnover · Short 100% of daily vol

Revenue

$9.1B +16.5% ▲

5Y CAGR: +11.4%

Gross Profit

$7.8B +17.9% ▲

5Y CAGR: +12.3%

Operating Income

$2.7B +11.1% ▲

5Y CAGR: +15.4%

Net Income

$2.1B +34.9% ▲

5Y CAGR: +16.5%

EPS (Diluted)

$0.85 +37.1% ▲

5Y CAGR: +17.5%

EBITDA

$3.3B +30.8% ▲

5Y CAGR: +14.7%

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$5.6B	$6.4B	$6.9B	$7.8B	$9.1B
YoY Growth	+5.1%	+14.2%	+7.5%	+13.9%	+16.5%
Cost of Revenue	$1.1B	$1.1B	$1.2B	$1.2B	$1.3B
Gross Profit	$4.5B	$5.3B	$5.7B	$6.6B	$7.8B
Gross Margin	81.0%	82.7%	82.7%	85.0%	86.0%
R&D Expenses	$590M	$754M	$693M	$795M	$1.3B
SG&A Expenses	$2.5B	$2.7B	$3.0B	$3.5B	$3.9B
Operating Expenses	$3.1B	$3.4B	$3.7B	$4.2B	$5.1B
Operating Income	$1.5B	$1.8B	$2.1B	$2.5B	$2.7B
Operating Margin	26.2%	28.6%	30.2%	31.5%	30.0%
Interest Expense	$81M	$67M	$103M	$212M	$191M
Income Before Tax	$979M	$1.9B	$2.3B	$2.0B	$2.7B
Tax Expense	$208M	$241M	$371M	$392M	$501M
Net Income	$836M	$1.7B	$1.9B	$1.5B	$2.1B
Net Margin	15.0%	25.9%	27.9%	19.8%	23.0%
EPS (Diluted)	$0.33	$0.62	$0.74	$0.62	$0.85
EBITDA	$1.7B	$2.3B	$2.8B	$2.5B	$3.3B
Shares Outstanding	2.75B	2.77B	2.65B	2.44B	2.47B

Line Item	FY2022 Q4	FY2023 Q2	FY2023 Q4	FY2024 Q2	FY2024 Q4	FY2025 Q2	FY2025 Q4	FY2026 Q2
Revenue	$3.8B	$3.8B	$4.0B	$4.4B	$4.7B	$4.4B	$13.1B	$4.5B
Cost of Revenue	$665M	$582M	$592M	$592M	$688M	$640M	$697M	$721M
Gross Profit	$3.1B	$3.2B	$3.4B	$3.8B	$4.0B	$3.7B	$12.4B	$3.7B
Gross Margin	82.4%	84.6%	85.3%	86.5%	85.4%	85.3%	94.7%	83.8%
R&D Expenses	$399M	$307M	$488M	$476M	$850M	$548M	$957M	$675M
SG&A Expenses	$1.6B	$1.6B	$1.9B	$1.8B	$2.1B	$1.9B	$2.3B	$1.5B
Operating Expenses	$2.0B	$2.1B	$2.4B	$2.3B	$2.8B	$2.4B	$3.3B	$2.1B
Operating Income	$1.0B	$1.3B	$1.1B	$1.5B	$1.2B	$1.3B	$9.1B	$1.6B
Operating Margin	27.4%	34.4%	26.1%	34.8%	25.5%	29.1%	69.7%	36.2%
Interest Expense	$149M	$201M	$11M	$0	$191M	$0	$23M	$30M
Income Before Tax	$1.2B	$1.2B	$784M	$1.4B	$1.3B	$1.6B	$9.0B	$1.4B
Tax Expense	$207M	$208M	$185M	$314M	$186M	$233M	$1.4B	$221M
Net Income	$949M	$981M	$569M	$1.1B	$1.0B	$1.4B	$7.0B	$1.1B
Net Margin	25.2%	25.9%	14.1%	24.8%	21.2%	31.2%	53.4%	25.3%
EPS (Diluted)	$0.36	$0.40	$0.23	$0.45	$0.40	$0.56	$2.87	$0.44
EBITDA	$1.2B	$1.5B	$769M	$1.7B	$1.6B	$1.4B	$9.4B	$1.9B
Shares Outstanding	2.62B	2.44B	2.44B	2.43B	2.47B	2.45B	2.47B	2.58B

TRSBF OTC